No Added Benefit From Chemo in This Breast Cancer Subtype No Added Benefit From Chemo in This Breast Cancer Subtype
Adding chemotherapy to endocrine therapy for women with ER-positive, HER2-negative invasive lobular carcinoma does not improve survival outcomes.Medscape Medical News
Source: Medscape Hematology-Oncology Headlines - Category: Cancer & Oncology Tags: Hematology-Oncology Source Type: news
More News: Breast Cancer | Breast Carcinoma | Cancer | Cancer & Oncology | Carcinoma | Chemotherapy | Endocrine Therapy | Hematology | HER2 | Lobular Carcinoma | Women